New drug combo shows promise in shrinking head and neck tumors before surgery
NCT ID NCT07492914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two drugs (lucanoximab and tagolimab) before surgery can shrink tumors in people with head and neck cancer. Thirty adults with resectable cancer will receive the drugs intravenously every two weeks for two cycles, then undergo surgery. Researchers will measure how many patients have a major response in their tumor tissue and track side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEAD AND NECK SQUAMOUS-CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
- Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
- Fewer radiation sessions may be safe for head and neck cancer patients
- New drug shows promise in shrinking head and neck tumors before surgery
- New combo attack on stubborn head and neck cancers enters early human testing
- Could a common drug make head and neck cancer treatment more effective?